Quick Answer
Entrada Therapeutics, Inc. reported Operating Income of -$157.90 million for fiscal year 2025.
Entrada Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$157.90M | -435.9% |
| 2024 | $47.01M | +1586.7% |
| 2023 | -$3.16M | +96.7% |
| 2022 | -$97.25M | -90.2% |
| 2021 | -$51.13M | -91.7% |
| 2020 | -$26.67M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$47.05M | -117.2% | -0.4% |
| June 30, 2025 | -$46.85M | -187.7% | -115.0% |
| March 31, 2025 | -$21.79M | -203.2% | -0.6% |
| September 30, 2024 | -$21.66M | -254.6% | -140.5% |
| June 30, 2024 | $53.42M | +427.8% | +153.0% |
| March 31, 2024 | $21.11M | +465.3% | +50.7% |
| September 30, 2023 | $14.01M | +154.0% | +186.0% |
| June 30, 2023 | -$16.30M | +30.9% | -182.0% |
- Entrada Therapeutics, Inc. showed a decrease of -435.9% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Entrada Therapeutics, Inc.’s operating income has declined by 492.1% (from -$26.67 million to -$157.90 million).
- The most recent figure is from Entrada Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: